AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Clinical trial NCT05244993 · UNKNOWN
Trial details
- NCT number
- NCT05244993
- Sponsor
- Liaoning Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2024-03-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.